1
|
Eichhorst A, Gallhof M, Voss A, Sekora A, Eggers L, Le Thi H, Junghanss C, Murua Escobar H, Brasholz M. Spirooxindol‐1,3‐oxazine alkaloids: highly potent and selective antitumor agents evolved from iterative structure optimization. ChemMedChem 2022; 17:e202200162. [PMID: 35491398 PMCID: PMC9400852 DOI: 10.1002/cmdc.202200162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2022] [Revised: 04/26/2022] [Indexed: 11/10/2022]
Abstract
Spirooxindole‐1,3‐oxazines are a small and structurally unique class of spirooxindole alkaloids. To date, only four of these compounds have been isolated from natural sources, and their biological properties remained unknown thus far. Dioxyreserpine is a synthetic spirooxindole‐1,3‐oxazine, that can readily be prepared from the Rauvolfia alkaloid (–)‐reserpine by catalytic photooxygenation. While dioxyreserpine itself was now identified as a moderately effective antitumoral agent, structurally modified analogs of it emerged as a new class of highly potent and selective growth inhibitors of various human cancers, including pancreatic cancers. Systematic structural optimization ultimately led to an inhibitor displaying low‐micromolar IC50‐values against six cancer cell lines as well as selective apoptosis induction in vitro.
Collapse
Affiliation(s)
- Annika Eichhorst
- Universitätsklinikum Rostock: Universitatsmedizin Rostock Department of Internal Medicine, Medical Clinic III GERMANY
| | - Malte Gallhof
- Universität Rostock Mathematisch-Naturwissenschaftliche Fakultät: Universitat Rostock Mathematisch-Naturwissenschaftliche Fakultat Institut für Chemie GERMANY
| | - Alice Voss
- Universität Rostock Mathematisch-Naturwissenschaftliche Fakultät: Universitat Rostock Mathematisch-Naturwissenschaftliche Fakultat Institut für Chemie GERMANY
| | - Anett Sekora
- Universitätsklinikum Rostock: Universitatsmedizin Rostock Department of Internal Medicine, Medical Clinic III GERMANY
| | - Leon Eggers
- Universitätsklinikum Rostock: Universitatsmedizin Rostock Department of Internal Medicine, Medical Clinic III GERMANY
| | - Huyen Le Thi
- Hanoi University of Science: Vietnam National University University of Science Institute of Chemistry GERMANY
| | - Christian Junghanss
- Universitätsklinikum Rostock: Universitatsmedizin Rostock Department of Internal Medicine, Medical Clinic III GERMANY
| | - Hugo Murua Escobar
- Universitätsklinikum Rostock: Universitatsmedizin Rostock Department of Internal Medicine, Medical Clinic III GERMANY
| | - Malte Brasholz
- Universitat Rostock Mathematisch-Naturwissenschaftliche Fakultat Institute of Chemistry Albert-Einstein-Str. 3a 18059 Rostock GERMANY
| |
Collapse
|
2
|
Weiner F, Schille JT, Koczan D, Wu XF, Beller M, Junghanss C, Hewicker-Trautwein M, Murua Escobar H, Nolte I. Novel chemotherapeutic agent FX-9 activates NF-κB signaling and induces G1 phase arrest by activating CDKN1A in a human prostate cancer cell line. BMC Cancer 2021; 21:1088. [PMID: 34625047 PMCID: PMC8501574 DOI: 10.1186/s12885-021-08836-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Accepted: 09/24/2021] [Indexed: 11/23/2022] Open
Abstract
Background The aminoisoquinoline FX-9 shows pro-apoptotic and antimitotic effects against lymphoblastic leukemia cells and prostate adenocarcinoma cells. In contrast, decreased cytotoxic effects against non-neoplastic blood cells, chondrocytes, and fibroblasts were observed. However, the actual FX-9 molecular mode of action is currently not fully understood. Methods In this study, microarray gene expression analysis comparing FX-9 exposed and unexposed prostate cancer cells (PC-3 representing castration-resistant prostate cancer), followed by pathway analysis and gene annotation to functional processes were performed. Immunocytochemistry staining was performed with selected targets. Results Expression analysis revealed 0.83% of 21,448 differential expressed genes (DEGs) after 6-h exposure of FX-9 and 0.68% DEGs after 12-h exposure thereof. Functional annotation showed that FX-9 primarily caused an activation of inflammatory response by non-canonical nuclear factor-kappa B (NF-κB) signaling. The 6-h samples showed activation of the cell cycle inhibitor CDKN1A which might be involved in the secondary response in 12-h samples. This secondary response predominantly consisted of cell cycle-related changes, with further activation of CDKN1A and inhibition of the transcription factor E2F1, including downstream target genes, resulting in G1-phase arrest. Matching our previous observations on cellular level senescence signaling pathways were also found enriched. To verify these results immunocytochemical staining of p21 Waf1/Cip1 (CDKN1A), E2F1 (E2F1), PAI-1 (SERPNE1), and NFkB2/NFkB p 100 (NFKB2) was performed. Increased expression of p21 Waf1/Cip1 and NFkB2/NFkB p 100 after 24-h exposure to FX-9 was shown. E2F1 and PAI-1 showed no increased expression. Conclusions FX-9 induced G1-phase arrest of PC-3 cells through activation of the cell cycle inhibitor CDKN1A, which was initiated by an inflammatory response of noncanonical NF-κB signaling. Supplementary Information The online version contains supplementary material available at 10.1186/s12885-021-08836-y.
Collapse
Affiliation(s)
- F Weiner
- Small Animal Clinic, University of Veterinary Medicine Hannover, 30559, Hannover, Germany.,Department of Medicine, Clinic III, Hematology, Oncology, Palliative Medicine, University of Rostock, 18057, Rostock, Germany
| | - J T Schille
- Small Animal Clinic, University of Veterinary Medicine Hannover, 30559, Hannover, Germany.,Department of Medicine, Clinic III, Hematology, Oncology, Palliative Medicine, University of Rostock, 18057, Rostock, Germany
| | - D Koczan
- Core Facility for Microarray Analysis, Institute for Immunology, University of Rostock, 18057, Rostock, Germany
| | - X-F Wu
- Leibniz Institute for Catalysis, 18059, Rostock, Germany
| | - M Beller
- Leibniz Institute for Catalysis, 18059, Rostock, Germany
| | - C Junghanss
- Department of Medicine, Clinic III, Hematology, Oncology, Palliative Medicine, University of Rostock, 18057, Rostock, Germany
| | - M Hewicker-Trautwein
- Department of Pathology, University of Veterinary Medicine Hannover, 30559, Hannover, Germany
| | - H Murua Escobar
- Department of Medicine, Clinic III, Hematology, Oncology, Palliative Medicine, University of Rostock, 18057, Rostock, Germany.,Comprehensive Cancer Center - Mecklenburg Vorpommern (CCC-MV), Campus Rostock, University of Rostock, 18057, Rostock, Germany
| | - I Nolte
- Small Animal Clinic, University of Veterinary Medicine Hannover, 30559, Hannover, Germany.
| |
Collapse
|
3
|
Weiner F, Schille JT, Hein JI, Wu XF, Beller M, Junghanß C, Murua Escobar H, Nolte I. Evaluation of combination protocols of the chemotherapeutic agent FX-9 with azacitidine, dichloroacetic acid, doxorubicin or carboplatin on prostate carcinoma cell lines. PLoS One 2021; 16:e0256468. [PMID: 34432846 PMCID: PMC8386839 DOI: 10.1371/journal.pone.0256468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2021] [Accepted: 08/06/2021] [Indexed: 11/25/2022] Open
Abstract
The isoquinolinamine FX-9 is a novel potential chemotherapeutic agent showing antiproliferative effects against hematologic and prostate cancer cell lines such as B- and T-acute lymphoblastic leukemia and prostate cancer (PC) of different species. Interestingly, FX-9 shows no hemolytic activity and low toxicity in benign adherent cells. The detailed FX-9 molecular mode of action is currently not fully understood. But application on neoplastic cells induces pro-apoptotic and antimitotic effects. Canine prostate cancer (cPC) represents a unique spontaneous occurring animal model for human androgen-independent PC. Human androgen-independent PC as well as cPC are currently not satisfactorily treatable with chemotherapeutic protocols. Accordingly, the evaluation of novel agent combinations bears significant potential for identifying novel treatment strategies. In this study, we combined FX-9 with the currently approved therapeutic agents doxorubicin, carboplatin, the demethylating substance azacitidine as well as further potentially antitumorigenic agents such as dichloroacetic acid (DCA) in order to evaluate the respective synergistic potential. The combinations with 1–5 μM FX-9 were evaluated regarding the effect after 72 hours on cell viability, cell count and apoptotic/necrotic cells in two human prostate cancer cell lines (LNCaP, PC-3) and a canine prostate cancer cell line (Adcarc1258) representing androgen-dependent and -independent PC/cPC forms. FX-9 in combination with azacitidine decreases cell viability and increases cell death with positive Bliss values. Furthermore, this decreases the cell count with neutral Bliss values on PC-3. Carboplatin in combination with FX-9 reduces cell viability with a neutral Bliss value and increases cell death on LNCaP with calculated positive Bliss values. DCA or doxorubicin in combination with FX-9 do not show synergistic or additive effects on the cell viability. Based on these results, azacitidine or carboplatin in combination with FX-9 offers synergistic/additive efficacy against prostate adenocarcinoma cell lines in vitro. The beneficial effects of both combinations are worth further investigation.
Collapse
Affiliation(s)
- Franziska Weiner
- Small Animal Clinic, University of Veterinary Medicine Hannover, Hannover, Germany
- Department of Medicine, Clinic III, Hematology, Oncology, Palliative Medicine, University of Rostock, Rostock, Germany
| | - Jan Torben Schille
- Small Animal Clinic, University of Veterinary Medicine Hannover, Hannover, Germany
- Department of Medicine, Clinic III, Hematology, Oncology, Palliative Medicine, University of Rostock, Rostock, Germany
| | - Jens Ingo Hein
- Small Animal Clinic, University of Veterinary Medicine Hannover, Hannover, Germany
| | - Xiao-Feng Wu
- Leibniz Institute for Catalysis, Rostock, Germany
| | | | - Christian Junghanß
- Department of Medicine, Clinic III, Hematology, Oncology, Palliative Medicine, University of Rostock, Rostock, Germany
| | - Hugo Murua Escobar
- Department of Medicine, Clinic III, Hematology, Oncology, Palliative Medicine, University of Rostock, Rostock, Germany
- * E-mail:
| | - Ingo Nolte
- Small Animal Clinic, University of Veterinary Medicine Hannover, Hannover, Germany
| |
Collapse
|
4
|
Brito ESA, Prado LDPT, Araújo LKC, Arnhold E, Matos MPC, de Paula JAM, Ramos LM, Fonseca-Alves CE, de Moura VMBD. Effects of the Latex of Synadenium grantii Hook F. ( Euphorbiaceae) on a Preclinical Model of Canine Prostate Cancer. Front Vet Sci 2021; 8:605286. [PMID: 33912602 PMCID: PMC8071850 DOI: 10.3389/fvets.2021.605286] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2020] [Accepted: 02/12/2021] [Indexed: 12/24/2022] Open
Abstract
Prostatic cancer (PC) stands out in terms of its occurrence, pathophysiology, and unfavorable prognostics in humans and dogs. Natural drugs bear an integrative potential for conventional antineoplastic treatments. In this context, the bioproducts of Synadenium grantii have been empirically used in different parts of Brazil for the integrative treatment of prostate cancer in humans. However, there is no availability of scientific evidence of the antitumor effects of S. grantii. Therefore, this study aimed to investigate the bioactive compounds in the latex of S. grantii using the high-resolution mass spectrophotometry (HRMS) and to evaluate its cytotoxic effects on primary canine PC cell cultures. Four fragments of phorbol ester were identified as potential bioactive compounds using the HRMS. With the help of an MTT ([3-(4,5-dimethyldiazol-2-yl)-2,5 diphenyltetrazolium bromide]) assay, two canine prostatic carcinoma cell lines (PC 1 and PC2) showed a decrease in the tumor cell count, with an Inhibitory concentration 50 (IC50)of 0.8469 and 0.6068 mg/ml, respectively, for PC1 and PC2. In conclusion, the latex of S. grantii contains phorbol esters in its composition, and its aqueous solution has a cytotoxic effect on canine metastatic PC cells in vitro.
Collapse
Affiliation(s)
| | | | | | - Emmanuel Arnhold
- Department of Animal Science, Federal University of Goiás UFG, Goiânia, Brazil
| | | | | | | | - Carlos Eduardo Fonseca-Alves
- Department of Veterinary Surgery and Animal Reproduction, São Paulo State University-UNESP, Botucatu, Brazil.,Institute of Health Sciences, University of São Paulo-UNIP, Bauru, Brazil
| | | |
Collapse
|